Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share
Executive Summary
Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA